SRM

Across TCGA pan-cancer cohorts, SRM Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SRM data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SRM Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SRM expression acts as an unfavorable survival marker.

LIHC, LUSC, and LGG are the cancer types where SRM Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.093	0.783	<.001	30	view →
LUSC	OS	Median	All	0.081	0.818	<.001	12	view →
LGG	DFS	Median	All	0.185	0.728	.006	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SRM–LIHC (OS)

Open the LIHC breakdown →